Clinical trials
Biliary Tract Carcinoma clinical trials
Below are recruiting biliary tract carcinoma clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT07641036RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Biliary Tract Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
Shenzhen, GuangdongAges 18 years+ - NCT06892925RecruitingPhase 2
Combination therapy for advanced bile duct cancer
This trial tests a new drug combination (QL1706 with lenvatinib and chemotherapy) as a first treatment for bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06181032RecruitingPhase 1
Immunotherapy and chemo combo before surgery for bile duct cancer
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Fuzhou, FujianAges 18–75 - NCT06622057RecruitingPhase 3
D07001 and capecitabine for advanced bile duct cancer
This trial tests a combination of two oral medications, D07001 and capecitabine, for people with advanced bile duct, gallbladder, or ampullary cancer that has gotten worse after standard chemotherapy. The goal is to see if this combination can help control the cancer.
Tucson, ArizonaAges 18 years+ - NCT07733115RecruitingPhase 2
Drug combo for advanced bile duct cancer
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
ShanghaiAges 18–75 - NCT07710885RecruitingPhase 3
Futibatinib for advanced bile duct cancer
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
BrisbaneAges 18 years+ - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT05065957RecruitingPhase 2/Phase 3
Study of two oral chemo medicines for advanced bile duct cancer
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
Kaohsiung CityAges 18 years+ - NCT06431490RecruitingPhase 1/Phase 2
Testing TQB2102 for HER2-positive bile duct cancer
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
Fuyang, AnhuiAges 18–75 - NCT06467357RecruitingPhase 3
A study of T-DXd and rilvegostomig for HER2-positive bile duct cancer
This trial tests a new combination of two drugs (T-DXd and rilvegostomig) for people with advanced bile duct cancer that has not been treated before. The cancer must have high levels of a protein called HER2. This study compares the new drugs to standard treatments.
Scottsdale, ArizonaAges 18–99 - NCT06546969RecruitingPhase 1
Combination therapy for advanced bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
Baltimore, MarylandAges 21 years+ - NCT06611345Recruiting
Tumor-treating fields with immunotherapy and chemo for bile duct cancer
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
HefeiAges 18–75 - NCT06938321RecruitingPhase 1/Phase 2
New drug combo for advanced bile duct and gallbladder cancer
This trial tests two new drugs, AK130 and AK112, for people with advanced bile duct or gallbladder cancer that has stopped responding to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07151118Recruiting
Blood test for advanced biliary tract cancer
This study uses a simple blood test (ctDNA) to learn more about the genetic makeup of advanced biliary tract cancers. It may help researchers understand how these cancers respond to treatment, and it doesn't involve any extra drugs or procedures—just blood draws.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07156058Recruiting
Personalized therapy after surgery for bile duct cancer
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
BeijingAges 18 years+ - NCT07267078RecruitingPhase 2
Tuvonralimab and Iparomlimab before surgery for bile duct cancer
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07679399RecruitingPhase 2
New combo therapy vs capecitabine for biliary tract cancer after surgery
This trial tests if a combination of immunotherapy (durvalumab), chemotherapy (GEMOX or GC), and a targeted therapy (lenvatinib) works better than standard capecitabine chemotherapy to prevent cancer from coming back after surgery for bile duct or gallbladder cancer.
BeijingAges 18–75 - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+ - NCT07636798RecruitingPhase 1/Phase 2
Chemotherapy and immunotherapy combination for advanced bile duct cancer
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
Chengdu, SichuanAges 18–75 - NCT07668453RecruitingPhase 2
Adebrelimab plus chemo for advanced bile duct cancer
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07670273RecruitingPhase 2
Drug combo for advanced HER2 bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
BeijingAges 18–75 - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05640791RecruitingPhase 2
Durvalumab with chemo before surgery for bile duct cancer
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary tract carcinoma?
- Yes. Clin2 currently lists 87 recruiting biliary tract carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary tract carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary tract carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.